Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027
[248 Pages Report] The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. The key driving factors of the market include, epigenetic enzymes gaining traction in drug discovery & development, rising investments, funds, and grants for epigenetics research, and declining costs of genome sequencing. Increase in the use of epigenetics in non-oncology applications is anticipated to offer profitable opportunities for market expansion. Limited applications of epigenomic data in toxicology and challenges associated with epigenetic editing may hinder the market growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Global Epigenetics Market Dynamics
DRIVER: Epigenetic enzymes gaining traction in drug discovery & development
Epigenetic drug discovery and development programs have been gaining traction recently due to large-scale investments and a growing focus on developing novel strategies to reverse epigenetic and transcriptional abnormalities. Epigenetic targets have emerged as the most promising classes of druggable targets. These targets have several research implications, including metabolic, oncology, neurology, inflammatory, and cardiovascular disorders.
RESTRAINT: Limited applications of epigenomic data in toxicology
Toxicology has seen the limited application of epigenomic data; an incomplete understanding of epigenomic variability has led to restricted knowledge on risk assessment across different tissue types and populations. This requires developing new solutions to ensure a comprehensive understanding of epigenetic mechanisms resulting in detailed epigenomic variation mapping. A key obstacle to the application of epigenomic analysis in toxicology is the lack of identification and consensus on a normal epigenome for all tissue and cell types.
The kits & reagents segment dominated the epigenetics market in 2021
Based on product & service, the global market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. Kits & reagents segment has generated highest revenue share in the market attributed to the increasing development of easy-to-use, affordable, and advanced epigenetics kits & reagents. This is further propelled by the exponential increase in the number of epigenetics research studies over the years. The kits & reagents are further segmented into antibodies, ChiP-seq kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC and 5-mC analysis kits, histones, and other kits & reagents. The software segment is expected to grow with the highest CAGR during the forecast period. Demand for software solutions has witnessed a significant increase in the epigenetics sequencing market space, epigenetics software solutions assist in the analysis of epigenetic modifications that are complex in nature.
Histone modifications is one of the lucrative segments in the epigenetics market, expected to grow at a high rate during the forecast period
Based on method, the global market is segmented into DNA methylation, histone modifications, and other methods. Different types of histone modifications are currently put to use in epigenetics studies, which include, ubiquitination, acetylation, citrullination, methylation, and phosphorylation. Research activities focusing on understanding the role of histone modifications in oncology as well non-oncology applications is expected to supplement the segment growth through the forecast period. DNA methylation represents the largest market share in 2021, increasing research on DNA methylation in non-oncology applications is expected to drive the segment growth.
NGS technique accounted for the largest share in the epigenetics market in 2021
Based on technique, the global market is segmented into NGS, PCR & qPCR, mass, spectrometry, sonication, and other techniques. Increase in demand for NGS platforms among research professionals to obtain clinically insightful and comprehensive datasets has contributed to the highest revenue generated by NGS segment in the market for the year 2021. Additionally, NGS solutions are gaining traction across mutational and epigenetic research activities, due their ability to sequence epigenomes rapidly. PCR and qPCR segment is expected to witness a rapid growth, registering the highest CAGR during the forecast period. Technological advancements in this market space is expected to propel the segment growth further.
Cardiovascular diseases application segment is expected to grow with the highest CAGR from 2020 to 2027 in the epigenetics market
Based on applications, the market is segmented into oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications. The role of epigenetics in understanding the etiology of CVDs is growing; research into treatment strategies for these diseases is expected to propel the adoption of epigenetics products. In October 2021, a research article was published on the significance of DNA methylation signatures in coronary heart disease (CHD). The study assessed the association between iCHD (incident CHD) and DNA methylation levels in the genome. This study concluded that the advent of epigenome-wide technologies had provided research professionals an opportunity to add study iCHD at an epigenetic level. Oncology applications dominated the market in 2021, attributed to the opportunities offered by epigenetic processes such as histone modification and DNA methylation to develop novel cancer therapeutic strategies.
Academic & research institutes have emerged as the dominant segment in the epigenetics market in 2021
Based on end users, the market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics. Increase in adoption of epigenetics products across government research institutions and university laboratories is the key revenue contributor to the academic & research institutes segment. Pharmaceutical & biotechnology companies segment is anticipated to grow at the fastest pace during the forecast period. Start-ups/SMEs are investing in the epigenetics market space to design innovative therapeutic strategies. In November 2021, a startup, Chroma Medicine, announced plans to develop epigenetic editors with the ability to alter how genes create proteins. This startup company is funded by Newpath Partners and Atlas Venture, among other investors, with a total of USD 125 million granted collectively. The company plans to employ gene-editing tools to develop drugs that can alter the epigenome, which serves as a novel approach for treating inherited diseases.
North America was the largest regional market for epigenetics in 2021.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North American market ranked the highest in terms of revenue in 2021, whereas Asia Pacific has emerged as the fastest growing regional market for epigenetics. US market is the key revenue contributor to North America epigenetics industry, this region harbors various leading product & service providers including, Pacific Biosciences (US), Thermo Fisher Scientific (US), and Illumina, Inc. (US). The lucrative growth registered by the Asia Pacific epigenetics industry is attributed to the improving healthcare infrastructure in the developing economies, which is set to open new avenues for business expansion for regional key market players.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
Key players in the global epigenetics market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
20202027 |
|
Base year considered |
2021 |
|
Forecast period |
20222027 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product & service, method, technique, application, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), F. Hoffmann-La Roche Ltd (Switzerland), EpiGentek Group Inc. (US), EpiCypher (US), Everon Life Sciences (India), Fios Genomics (UK), GenomeScan (Netherlands), and Creative Biogene (US). |
This report categorizes the epigenetics market into the following segments
By Product & Service
- Kits & Reagents
- Antibodies
- ChiP-seq Kits
- Bisulfite Conversion Kits
- Whole Genome Amplification Kits
- 5-hmC and 5-mC Analysis Kits
- Histones
- Other Kits & Reagents
- Enzymes
- DNA-modifying Enzymes
- Protein-modifying Enzymes
- Other Enzymes
- Instruments and Accessories
- Software
- Service
By Method
- DNA Methylation
- Histone Modifications
- Other Methods
By Technique
- NGS
- PCR & qPCR
- Mass Spectrometry
- Sonication
- Other Techniques
By Application
- Oncology
- Metabolic Diseases
- Immunology
- Developmental Biology
- Cardiovascular Diseases
- Other Applications
By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In 2022, PacBio introduced DNA methylation capabilities via its product line, Sequel, in the US. Introducing this feature to the Sequel systems is expected to extend the accessibility of epigenomes via HiFi sequencing developed by the company.
- In 2021, Proteintech Group is engaged in manufacturing nanobodies, antibodies, and recombinant proteins, has extended its collaboration with Active Motif.
- In 2019, New England BioLabs launched an alternative to bisulfite sequencing, NEBNext Enzymatic Methyl-seq (EM-seq), in the US. This is an enzyme-based product for methylation analysis.
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on the epigenetics market?
Epigenetics is a comparatively new industry dealing with the genetic and non-genetic aspects of heritable phenotypic changes, mostly caused by environmental and metabolic factors. SARS-CoV-2 is a highly pathogenic and transmittable infection, the severity and consequences of which heavily rely on patient age and overall health condition. Thus, this virus regulates the host epigenome in various ways; a better understanding is required to help design novel therapeutic strategies for this pandemic. This potential application of epigenetics has spiked the interest of researchers, creating a positive impact on the overall epigenetics market.
Who are the key players in the epigenetics market?
Key players in the global epigenetics market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
Which product dominates in the epigenetics market?
Kits & reagents segment has generated highest revenue share in the market attributed to the increasing development of easy-to-use, affordable, and advanced epigenetics kits & reagents.
Which method segment of the global epigenetics market is expected to witness the highest growth?
Research activities focusing on understanding the role of histone modifications in oncology as well non-oncology applications is expected to supplement the segment growth.
What is the market for epigenetics?
The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 34)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 EPIGENETICS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EPIGENETICS IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 EPIGENETICS MARKET: CAGR PROJECTIONS, 20222027
FIGURE 8 EPIGENETICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 12 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2027 (USD MILLION)
FIGURE 13 MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)
FIGURE 14 MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION)
FIGURE 15 MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION)
FIGURE 16 MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT: EPIGENETICS MARKET
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 EPIGENETICS MARKET OVERVIEW
FIGURE 18 GROWING USE OF EPIGENETIC ENZYMES IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2021)
FIGURE 19 KITS & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2021
4.3 NORTH AMERICA: MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION)
FIGURE 20 DNA METHYLATION TO DOMINATE THE NORTH AMERICAN MARKET TILL 2027
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 EPIGENETICS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Epigenetic enzymes gaining traction in drug discovery & development
TABLE 2 KEY EPIGENETIC ENZYMES FOR REPURPOSING DRUGS
5.2.1.2 Rising investments, funds, and grants for epigenetics research
5.2.1.3 Declining costs of genome sequencing
FIGURE 22 COST OF HUMAN WHOLE-GENOME SEQUENCING, 20012020
5.2.2 RESTRAINTS
5.2.2.1 Limited applications of epigenomic data in toxicology
5.2.3 OPPORTUNITIES
5.2.3.1 Use of epigenetics in non-oncology applications
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with epigenetic editing
5.2.4.1.1 Off-target effect
5.2.4.1.2 Other challenges
5.3 SCENARIOS ARISING OUT OF UNCERTAINTIES AFFECTING MARKET GROWTH
FIGURE 23 IMPACT OF UNCERTAINTIES ON MARKET GROWTH
5.4 IMPACT OF COVID-19 ON THE EPIGENETICS MARKET
TABLE 3 EPIGENETIC IMPLICATIONS IN CORONAVIRUS INFECTION AND THERAPY
5.5 PORTERS FIVE FORCES ANALYSIS
TABLE 4 EPIGENETICS MARKET: PORTERS FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 ECOSYSTEM ANALYSIS
FIGURE 24 ECOSYSTEM ANALYSIS: EPIGENETICS MARKET
5.7 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: EPIGENETICS MARKET
5.8 SUPPLY CHAIN ANALYSIS
TABLE 5 SUPPLY CHAIN ECOSYSTEM
5.9 REGULATORY ANALYSIS
TABLE 6 KEY REGULATORY AGENCIES
6 EPIGENETICS MARKET, BY PRODUCT & SERVICE (Page No. - 72)
6.1 INTRODUCTION
TABLE 7 MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
6.2 KITS & REAGENTS
TABLE 8 EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 9 EPIGENETIC KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 10 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 11 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 12 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Increasing demand for recombinant antibodies for the detection of epigenetic targets propels the segment growth
TABLE 13 ANTIBODIES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 14 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 15 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 16 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.2 CHIP-SEQUENCING KITS & REAGENTS
6.2.2.1 Versatile applications of ChIP in epigenetic regulatory systems contribute to the segments dominant share
TABLE 17 CHIP-SEQ KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 18 NORTH AMERICA: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 19 EUROPE: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 20 ASIA PACIFIC: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.3 BISULFITE CONVERSION KITS & REAGENTS
6.2.3.1 Effectiveness of bisulfite conversion in gene-specific and genome-wide analyses to drive the demand for kits & reagents
TABLE 21 BISULFITE CONVERSION KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 22 NORTH AMERICA: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 23 EUROPE: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 24 ASIA PACIFIC: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
6.2.4.1 Whole-genome amplification maintains the relative proportions of genes present in the original pool, increasing its preference among researchers
TABLE 25 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 26 NORTH AMERICA: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 27 EUROPE: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 28 ASIA PACIFIC: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
6.2.5.1 Introduction of unique kits drives market growth
TABLE 29 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 30 NORTH AMERICA: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 31 EUROPE: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 32 ASIA PACIFIC: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.6 HISTONES
6.2.6.1 Importance of chromatin-associated proteins & histones in epigenetic research to drive the segment growth
TABLE 33 HISTONES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 34 NORTH AMERICA: HISTONES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 35 EUROPE: HISTONES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 36 ASIA PACIFIC: HISTONES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.2.7 OTHER KITS & REAGENTS
TABLE 37 OTHER KITS & REAGENTS MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 38 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 39 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 40 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.3 ENZYMES
TABLE 41 EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 42 EPIGENETIC ENZYMES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 43 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 44 EUROPE: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 45 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.3.1 DNA-MODIFYING ENZYMES
6.3.1.1 Growing applications of DNA methylation to contribute to the segments dominant share
TABLE 46 DNA-MODIFYING ENZYMES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 47 NORTH AMERICA: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 48 EUROPE: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 49 ASIA PACIFIC: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.3.2 PROTEIN-MODIFYING ENZYMES
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive the segment growth
TABLE 50 PROTEIN-MODIFYING ENZYMES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 51 NORTH AMERICA: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 52 EUROPE: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 53 ASIA PACIFIC: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.3.3 OTHER ENZYMES
TABLE 54 OTHER ENZYMES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 55 NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 56 EUROPE: OTHER ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 57 ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.4 INSTRUMENTS & ACCESSORIES
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO CONTRIBUTE TO THE SEGMENT REVENUE
TABLE 58 EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 59 NORTH AMERICA: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 60 EUROPE: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 61 ASIA PACIFIC: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.5 SOFTWARE
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION, CHROMATIN, AND RNA ANALYSIS TO PROPEL SEGMENT GROWTH
TABLE 62 EPIGENETIC SOFTWARE MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 63 NORTH AMERICA: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 64 EUROPE: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 65 ASIA PACIFIC: EPIGENETIC SOFTWARE MARKET, BY COUNTRY, 20202027 (USD MILLION)
6.6 SERVICES
6.6.1 EXPANDING POOL OF PROVIDERS TO DRIVE THE SERVICES SEGMENT
TABLE 66 EPIGENETIC SERVICES MARKET, BY REGION, 20202027 (USD MILLION)
TABLE 67 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 68 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 69 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 20202027 (USD MILLION)
7 EPIGENETICS MARKET, BY METHOD (Page No. - 100)
7.1 INTRODUCTION
TABLE 70 MARKET, BY METHOD, 20202027 (USD MILLION)
7.2 DNA METHYLATION
7.2.1 DNA METHYLATION TO DOMINATE THE METHODS MARKET TILL 2027
TABLE 71 MARKET FOR DNA METHYLATION, BY REGION, 20202027 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR DNA METHYLATION, BY COUNTRY, 20202027 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR DNA METHYLATION, BY COUNTRY, 20202027 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR DNA METHYLATION, BY COUNTRY, 20202027 (USD MILLION)
7.3 HISTONE MODIFICATIONS
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENT GROWTH
TABLE 75 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 76 EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 20202027 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 78 EUROPE: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 20202027 (USD MILLION)
7.4 OTHER METHODS
TABLE 80 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 20202027 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR OTHER METHODS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR OTHER METHODS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR OTHER METHODS, BY COUNTRY, 20202027 (USD MILLION)
8 EPIGENETICS MARKET, BY TECHNIQUE (Page No. - 108)
8.1 INTRODUCTION
TABLE 84 MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
8.2 NGS
8.2.1 NGS OFFERS COMPREHENSIVE EPIGENETIC PROFILES, WHICH DRIVES ADOPTION
TABLE 85 EPIGENETICS MARKET FOR NGS, BY REGION, 20202027 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET FOR NGS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 87 EUROPE: MARKET FOR NGS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 88 ASIA PACIFIC: MARKET FOR NGS, BY COUNTRY, 20202027 (USD MILLION)
8.3 PCR & QPCR
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO PROPEL THE SEGMENT GROWTH
TABLE 89 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 20202027 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR PCR & QPCR, BY COUNTRY, 20202027 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR PCR & QPCR, BY COUNTRY, 20202027 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR PCR & QPCR, BY COUNTRY, 20202027 (USD MILLION)
8.4 MASS SPECTROMETRY
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN HISTONE EPIGENETICS STUDIES TO DRIVE THE SEGMENT GROWTH
TABLE 93 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 20202027 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 20202027 (USD MILLION)
8.5 SONICATION
8.5.1 ADVENT OF IMPROVED HIGH-THROUGHPUT SONICATION TO PROPEL ITS ADOPTION IN EPIGENETICS STUDIES
TABLE 97 EPIGENETICS MARKET FOR SONICATION, BY REGION, 20202027 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET FOR SONICATION, BY COUNTRY, 20202027 (USD MILLION)
TABLE 99 EUROPE: MARKET FOR SONICATION, BY COUNTRY, 20202027 (USD MILLION)
TABLE 100 ASIA PACIFIC: MARKET FOR SONICATION, BY COUNTRY, 20202027 (USD MILLION)
8.6 OTHER TECHNIQUES
TABLE 101 EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 20202027 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 103 EUROPE: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 20202027 (USD MILLION)
9 EPIGENETICS MARKET, BY APPLICATION (Page No. - 119)
9.1 INTRODUCTION
TABLE 105 MARKET, BY APPLICATION, 20202027 (USD MILLION)
9.2 ONCOLOGY
9.2.1 ONCOLOGY TO HOLD LARGEST SHARE OF THE APPLICATIONS SEGMENT TILL 2027
TABLE 106 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
TABLE 107 MARKET FOR ONCOLOGY, BY REGION, 20202027 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 109 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 20202027 (USD MILLION)
9.3 METABOLIC DISEASES
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO DRIVE THE SEGMENT GROWTH
TABLE 111 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 20202027 (USD MILLION)
TABLE 112 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 113 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 114 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 20202027 (USD MILLION)
9.4 IMMUNOLOGY
9.4.1 RISING DEMAND FOR EPIGENETICS PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE SEGMENTS GROWTH
TABLE 115 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 20202027 (USD MILLION)
TABLE 116 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 117 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 118 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 20202027 (USD MILLION)
9.5 DEVELOPMENTAL BIOLOGY
9.5.1 GROWING R&D IN DEVELOPMENTAL BIOLOGY TO PROPEL THE SEGMENTS GROWTH
TABLE 119 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 20202027 (USD MILLION)
TABLE 120 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 121 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 20202027 (USD MILLION)
TABLE 122 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 20202027 (USD MILLION)
9.6 CARDIOVASCULAR DISEASES
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING THE ETIOLOGY OF CARDIOVASCULAR DISEASES TO PROPEL PRODUCT ADOPTION
TABLE 123 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 20202027 (USD MILLION)
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 125 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 20202027 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 127 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 20202027 (USD MILLION)
TABLE 128 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 129 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 130 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20202027 (USD MILLION)
10 EPIGENETICS MARKET, BY END USER (Page No. - 133)
10.1 INTRODUCTION
TABLE 131 EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 HIGH SHARE ATTRIBUTED TO RISING COLLABORATIONS AMONG RESEARCH INSTITUTES AND DEMAND FOR CANCER EPIGENETICS
TABLE 132 EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 20202027 (USD MILLION)
TABLE 133 NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 134 EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 135 ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 20202027 (USD MILLION)
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 HIGH NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE THE SEGMENT GROWTH
TABLE 136 EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 20202027 (USD MILLION)
TABLE 137 NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 138 EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20202027 (USD MILLION)
TABLE 139 ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20202027 (USD MILLION)
10.4 HOSPITALS & CLINICS
10.4.1 RISING IMPORTANCE OF DNA METHYLATION MEASUREMENTS TO DRIVE SEGMENT GROWTH
TABLE 140 EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 20202027 (USD MILLION)
TABLE 141 NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 142 EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 20202027 (USD MILLION)
TABLE 143 ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 20202027 (USD MILLION)
11 EPIGENETICS MARKET, BY REGION (Page No. - 141)
11.1 INTRODUCTION
TABLE 144 EPIGENETICS MARKET, BY REGION, 20202027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 146 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 147 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 148 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 149 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 150 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 151 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.2.1 US
11.2.1.1 A strong network of well-established epigenetic product manufacturers is the key growth contributor
TABLE 153 US: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 154 US: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 155 US: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 156 US: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 157 US: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 158 US: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 159 US: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Government initiatives to boost epigenetics research contribute to the market growth
TABLE 160 CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 161 CANADA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 162 CANADA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 163 CANADA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 164 CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 165 CANADA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 166 CANADA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.3 EUROPE
TABLE 167 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 168 EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 169 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 170 EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 171 EUROPE: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 172 EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 173 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 174 EUROPE: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Significant investments in the NGS market space in Germany expected to boost the uptake of epigenetics products
TABLE 175 GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 176 GERMANY: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 177 GERMANY: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 178 GERMANY: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 179 GERMANY: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 180 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 181 GERMANY: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.3.2 UK
11.3.2.1 Rising acceptance of genome-based diagnostic techniques to drive the UK epigenetics market
TABLE 182 UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 183 UK: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 184 UK: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 185 UK: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 186 UK: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 187 UK: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 188 UK: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing demand for PCR technologies propelled by favorable government initiatives to boost the market growth
TABLE 189 FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 190 FRANCE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 191 FRANCE: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 192 FRANCE: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 193 FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 194 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 195 FRANCE: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 196 REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 197 REST OF EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 198 REST OF EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 199 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 200 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 201 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 202 REST OF EUROPE: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
TABLE 203 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 20202027 (USD MILLION)
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 205 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 206 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 207 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 208 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 209 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 210 ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Research-academia collaborations have driven awareness of epigenetics in the country
TABLE 211 JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 212 JAPAN: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 213 JAPAN: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 214 JAPAN: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 215 JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 216 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 217 JAPAN: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Increasing research on genomics and high demand for personalized medicine to propel the Chinese market
TABLE 218 CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 219 CHINA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 220 CHINA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 221 CHINA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 222 CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 223 CHINA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 224 CHINA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Activities to strengthen genomics research by expanding the base of biotechnology facilities to drive market growth
TABLE 225 INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 226 INDIA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 227 INDIA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 228 INDIA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 229 INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 230 INDIA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 231 INDIA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 232 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 233 REST OF ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 234 REST OF ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 ADVANCEMENTS IN EPIGENETIC ANALYSIS AND CHARACTERIZATION TO BOOST THE UPTAKE OF MARKET PRODUCTS
TABLE 239 LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 240 LATIN AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 241 LATIN AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 242 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 243 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 244 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 245 LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING FUNDING AND PARTNERSHIPS IN RESEARCH TO BOOST MARKET GROWTH IN THE MIDDLE EAST & AFRICA
TABLE 246 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 20202027 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 248 MIDDLE EAST & AFRICA: EPIGENETIC ENZYMES MARKET, BY TYPE, 20202027 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY METHOD, 20202027 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY TECHNIQUE, 20202027 (USD MILLION)
TABLE 251 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY APPLICATION, 20202027 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY END USER, 20202027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 189)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 EPIGENETICS MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 29 EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF TOP 5 PLAYERS (2021)
12.4 REVENUE SHARE ANALYSIS (TOP 5 MARKET PLAYERS)
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST 2-3 YEARS
12.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2021
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPETITIVE BENCHMARKINGSTARTUPS/SMES
TABLE 253 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 254 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 PRODUCT LAUNCHES
TABLE 255 EPIGENETICS MARKET: PRODUCT LAUNCHES
12.6.2 DEALS
TABLE 256 EPIGENETICS MARKET: ACQUISITIONS
13 COMPANY PROFILES (Page No. - 197)
13.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.1.2 ILLUMINA, INC.
TABLE 258 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT
13.1.3 PACIFIC BIOSCIENCES
TABLE 259 PACBIO: BUSINESS OVERVIEW
FIGURE 34 PACBIO: COMPANY SNAPSHOT
13.1.4 ABCAM PLC.
TABLE 260 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC: COMPANY SNAPSHOT
13.1.5 MERCK KGAA
TABLE 261 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT
13.1.6 BIO-RAD LABORATORIES, INC.
TABLE 262 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 37 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
13.1.7 ACTIVE MOTIF
TABLE 263 ACTIVE MOTIF: BUSINESS OVERVIEW
13.1.8 NEW ENGLAND BIOLABS
TABLE 264 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW
13.1.9 QIAGEN
TABLE 265 QIAGEN: BUSINESS OVERVIEW
FIGURE 38 QIAGEN: COMPANY SNAPSHOT
13.1.10 ZYMO RESEARCH CORPORATION
TABLE 266 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW
13.1.11 PERKINELMER INC.
TABLE 267 PERKINELMER INC.: BUSINESS OVERVIEW
13.1.12 DIAGENODE
TABLE 268 DIAGENODE: BUSINESS OVERVIEW
13.1.13 F. HOFFMANN-LA ROCHE LTD
TABLE 269 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
13.1.14 PROMEGA CORPORATION
TABLE 270 PROMEGA CORPORATION: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 EPIGENTEK GROUP INC.
13.2.2 EPICYPHER
13.2.3 EVERON LIFE SCIENCES
13.2.4 FIOS GENOMICS
13.2.5 GENOMESCAN
13.2.6 CREATIVE BIOGENE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 240)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the epigenetics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the epigenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochemistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences, Canadian Institutes of Health Research, and Genome Canada, Annual Reports, SEC Filings, Investor Presentations, Press Releases, Conferences, Journals, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the epigenetics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the epigenetics business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global epigenetics market based on the product & service, method, technique, application, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyse micromarkets with respect to individual growth trends, future prospects, and contributions to the overall epigenetics market
- To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the epigenetics market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Epigenetics Market News
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
Growth opportunities and latent adjacency in Epigenetics Market